Tag: results

BEERSE, BELGIUM, June 26, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced new data across 12 abstracts at the European Academy of Neurology (EAN) 2026 Congress that offer additional insight into the use of IMAAVY^®▼(nipocalimab) throughout clinically relevant points in the generalised myasthenia gravis (gMG) treatment journey. The analyses include adults with anti-AChR^a or anti-MuSK^b antibody-positive gMG who were early in their disease course or had lower baseline symptom burden – providing insight into the potential importance of addressing pathogenic immunoglobulin G (IgG) early in disease progression where use of advanced therapies may be less common.^1,2 Additional research to be shared include outcomes shortly after common infections, which are a known cause of disease exacerbations in gMG, and plans to address evidence gaps in the use of nipocalimab during pregnancy.^3,4

London, United Kingdom, June 26, 2026 (GLOBE NEWSWIRE) --

BulkQuant, a fully managed AI trading robot platform, is expanding its automated trading ecosystem to help retail investors explore structured trading strategies across cryptocurrency, forex, and stock market environments.

MERIDIAN, Idaho, June 26, 2026 (GLOBE NEWSWIRE) -- PCS Edventures!, Inc. (“PCSV”), a leading provider of TK-12 Science, Technology, Engineering and Mathematics (“STEM”) education programs, today announced results of operations for its fiscal year ended March 31, 2026.

CALGARY, Alberta and BOGOTÁ, Colombia, June 26, 2026 (GLOBE NEWSWIRE) -- Canacol Energy Ltd. ("Canacol" or the "Company") (TSX: CNE), a leading natural gas exploration and production company operating in Colombia, today announced that the Court of King's Bench of Alberta issued a decision on June 24, 2026, granting Canacol permission to disclaim natural gas supply and transportation contracts as part of its ongoing restructuring under the Companies' Creditors Arrangement Act (CCAA).

Oslo, 26 June 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today announces that the NSGO-CTU sponsored Phase II DOVACC clinical trial (NCT04742075) investigating the Ultimovacs UV1 cancer vaccine, inherited through the business combination between the two companies in 2025, did not meet the primary endpoint. This concludes the previously communicated wrap-up phase of the UV1 cancer vaccine programme and Zelluna now considers the programme closed.